El Salvador, Guatemala, Honduras II treatment protocol: continuation therapy for patients with high-risk acute lymphocytic leukemia (ALL).
| Week 1 | Dexamethasone | 12 mg/m2 PO daily x 7 |
| Vincristine | 1.5 mg/m2 IV | |
| Week 2 | Cyclophosphamide | 300 mg/m2 IV |
| Mercaptopurine | 75 mg/m2 PO daily x 7 | |
| Week 3 | Methotrexate | 40 mg/m2 IV/IM |
| Mercaptopurine | 75 mg/m2 PO daily x 7 | |
| Week 4 | Methotrexate | 40 mg/m2 IV/IM |
| Cytarabine | 300 mg/m2 IV | |
| Week 5 | Dexamethasone | 12 mg/m2 PO daily |
| Vincristine | 1.5 mg/m2 IV | |
| Week 6 | Cyclophosphamide | 300 mg/m2 IV |
| Mercaptopurine | 75 mg/m2 PO daily | |
| Weeks 7-11 | Repeat induction and consolidation | |
| Week 12 | Dexamethasone | 12 mg/m2 PO daily x 7 |
| Vincristine | 1.5 mg/m2 IV | |
| L-asparaginase | 10,000 I.U./m2 IV | |
| Week 13 | Cyclophosphamide | 300 mg/m2 IV |
| Mercaptopurine | 75 mg/m2 PO daily x 7 | |
| Week 14 | Methotrexate | 40 mg/m2 IV/IM |
| Cytarabine | 300 mg/m2 IV | |
| Week 15 | Dexamethasone | 12 mg/m2 PO daily |
| Vincristine | 1.5 mg/m2 IV | |
| L-asparaginase | 10,000 I.U./m2 IV | |
| Week 16 | Cyclophosphamide | 300 mg/m2 IV weekly |
| Mercaptopurine | 75 mg/m2 PO daily x 7 | |
| Weeks 17-20 | Repeat induction and consolidation | |
| Week 21 | Dexamethasone | 12 mg/m2 PO daily |
| Vincristine | 1.5 mg/m2 IV | |
| Week 22 | Mercaptopurine | 75 mg/m2 PO daily x 7 |
| Cyclophosphamide | 300 mg/m2 IV weekly | |
| Week 23 | Mercaptopurine | 75 mg/m2 PO daily x 7 |
| Methotrexate | 40 mg/m2 IV/IM | |
| Week 24 | Mercaptopurine | 75 mg/m2 PO daily x 7 |
| Methotrexate | 3.0 g/m2 | |
| The following drug pairs are given weekly in sequence: dexamethasone plus vincristine; mercaptopurine plus cyclophosphamide; mercaptopurine plus methotrexate; methotrexate plus cytarabine; and mercaptopurine plus methotrexate. | ||
| The high-dose methotrexate plus mercaptopurine course is given every 6 weeks for a total of 6 courses during the first year of continuation therapy. | ||
| Triple IT is given on weeks 1, 2, 3, 7, 10, 12, 20, 24, 28, 31, 36, 39, 43, 47, 51 54, 55, 56 | ||
| Week 1 | Dexamethasone | 12 mg/m2 PO daily x 7 |
| Vincristine | 1.5 mg/m2 IV | |
| Week 2 | Cyclophosphamide | 300 mg/m2 IV |
| Mercaptopurine | 75 mg/m2 PO daily x 7 | |
| Week 3 | Methotrexate | 40 mg/m2 IV/IM |
| Mercaptopurine | 75 mg/m2 PO daily x 7 | |
| Week 4 | Methotrexate | 40 mg/m2 IV/IM |
| Cytarabine | 300 mg/m2 IV | |
| Week 5 | Dexamethasone | 12 mg/m2 PO daily |
| Vincristine | 1.5 mg/m2 IV | |
| Week 6 | Cyclophosphamide | 300 mg/m2 IV |
| Mercaptopurine | 75 mg/m2 PO daily | |
| Weeks 7-11 | Repeat induction and consolidation | |
| Week 12 | Dexamethasone | 12 mg/m2 PO daily x 7 |
| Vincristine | 1.5 mg/m2 IV | |
| L-asparaginase | 10,000 I.U./m2 IV | |
| Week 13 | Cyclophosphamide | 300 mg/m2 IV |
| Mercaptopurine | 75 mg/m2 PO daily x 7 | |
| Week 14 | Methotrexate | 40 mg/m2 IV/IM |
| Cytarabine | 300 mg/m2 IV | |
| Week 15 | Dexamethasone | 12 mg/m2 PO daily |
| Vincristine | 1.5 mg/m2 IV | |
| L-asparaginase | 10,000 I.U./m2 IV | |
| Week 16 | Cyclophosphamide | 300 mg/m2 IV weekly |
| Mercaptopurine | 75 mg/m2 PO daily x 7 | |
| Weeks 17-20 | Repeat induction and consolidation | |
| Week 21 | Dexamethasone | 12 mg/m2 PO daily |
| Vincristine | 1.5 mg/m2 IV | |
| Week 22 | Mercaptopurine | 75 mg/m2 PO daily x 7 |
| Cyclophosphamide | 300 mg/m2 IV weekly | |
| Week 23 | Mercaptopurine | 75 mg/m2 PO daily x 7 |
| Methotrexate | 40 mg/m2 IV/IM | |
| Week 24 | Mercaptopurine | 75 mg/m2 PO daily x 7 |
| Methotrexate | 3.0 g/m2 | |
| The following drug pairs are given weekly in sequence: dexamethasone plus vincristine; mercaptopurine plus cyclophosphamide; mercaptopurine plus methotrexate; methotrexate plus cytarabine; and mercaptopurine plus methotrexate. | ||
| The high-dose methotrexate plus mercaptopurine course is given every 6 weeks for a total of 6 courses during the first year of continuation therapy. | ||
| Triple IT is given on weeks 1, 2, 3, 7, 10, 12, 20, 24, 28, 31, 36, 39, 43, 47, 51 54, 55, 56 | ||